BioSpace News Archive

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022.

Grifols announced a collaboration with Endpoint Health, Inc., a precision-medicine therapeutics company dedicated to addressing urgent needs in immune-driven critical care, to develop and commercialize an Antithrombin III therapy to treat Sepsis.

United Therapeutics Corporation, a public benefit corporation, announced its financial results for the fourth quarter and year ended December 31, 2021.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced the commercial unveiling of the CosMx™ Spatial Molecular Imager to occur at the fourth annual virtual Spatial Genomics Summit on Monday, Feb. 28 from 8-10 a.m..

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported financial results for the fourth quarter and full-year periods ended December 31, 2021 and provided an update on recent company developments.

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today reported business highlights and financial results for the fourth quarter and full year 2021.

Immunic, Inc. announced financial results for the fourth quarter and year ended December 31, 2021 and highlighted recent activity.

IVERIC bio, Inc. (Nasdaq: ISEE) today announced financial and operating results for the fourth quarter and full year ended December 31, 2021 and provided a general business update.

Karuna Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2021, and provided a general business update.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the fourth quarter and full year of 2021 and provided a corporate update.